Oppenheimer Touts Boston Scientific Corporation (BSX) as the Best Large-Cap MedTech

Boston Scientific Corporation (NYSE:BSX) is one of the best defensive stocks to buy, according to Steve Cohen. On September 8, analysts at Oppenheimer upgraded the stock to an ‘Outperform’ from Perform and reiterated a $125 price target.

The upgrade comes as Oppenheimer views the company as one of the best large-cap MedTech growth stories owing to a robust merger and acquisition strategy. The company has delivered a strong performance, with 21.44% revenue growth over the past 12 months.

In addition, the research firm has echoed the company’s projected 11%-13% compound annual growth rate outlook. It is a positive attribute for a highly diversified company in the healthcare sector. Its competitive edge was the catalyst behind a 17% organic revenue growth in the second quarter of 2025 as earnings per share increased 23%.

Boston Scientific Corporation (NYSE:BSX) is a global medical technology company that develops and manufactures innovative devices and solutions to diagnose and treat a wide range of complex medical conditions, including cardiovascular, respiratory, digestive, neurological, and urological diseases.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Wind Power and Solar Stocks to Buy According to Analysts and 10 Best Robinhood Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.